Vorinostat (Zolinza) is now available on the PBS for patients with relapsed or refractory cutaneous T-cell lymphoma, following a successful submission by patient advocacy group Rare Cancers Australia. This is believed to be the first time a drug has been sponsored through the PBAC approval process by a community organisation rather than a pharmaceutical company. ...
Advocacy for rare cancer drug pays off
By Mardi Chapman
4 Jul 2017